The earliest signal of disease is often the hardest to read. Xzōm harnesses extracellular vesicles (exosomes) — biology's continuously-secreted messengers — using a proprietary Alternating Current Electrokinetics (ACE) platform to isolate and analyze them from under 100 microliters of blood in less than 30 minutes. The pioneering target: early detection of cancer, with a pipeline across oncology and other critical disease areas where timely detection can transform outcomes.
Connected the team to diagnostics experts, customers, and fellow investors — before and after our investment.